Extrahepatic manifestations of chronic hepatitis C

Replication of hepatitis C virus is possible not only in the target organ liver cells, but also in the vascular endothelium, mononuclear cells, B lymphocytes, macrophages, bone marrow, myocardium, skin and endocrine glands, which explains the disease clinical diversity and extrahepatic manifestations in HCVpatients. Extrahepatic manifestations range from 50 % to 74 %. Kidneys are the most common target organs for extrahepatic manifestations of chronic hepatitis C. Renal irritation can lead to chronic HCV infection. Kidney disease can occur due to HCV influence on the renal epithelium and cryoglobulinemia development. The purpose of our paper is to increase the doctors' alertness to HCV, its atypical course, and the onset of extrahepatic manifestations. Correct and timely diagnosis and etiotropic therapy will lead to an improvement in the patient's clinical status. Treatment of chronic HCV infection is a multisystem problem that any physician can face. Etiotropic therapy for chronic hepatitis C leads not only to virus elimination, but also to the relief of extrahepatic manifestations. Combination therapy with direct antiviral drugs (glecaprevir + pibrentasvir) has proven its effectiveness in patients with extrahepatic manifestations. Sustainable virological response allows not only to stop degenerative changes in the liver, but also to reduce the clinical symptoms of extrahepatic manifestations of chronic HCV infection, reduce the disability rate in the working population, and improve the quality of life.